Samsung Bioepis has launched Phase 1 clinical trials for its antibody-drug conjugate (ADC) candidate, SBE303. This marks the company’s first venture into new drug development.
According to ClinicalTrials.gov, a U.S. website providing clinical trial information, Samsung Bioepis commenced Phase 1 trials for SBE303 last month. The study, involving 149 patients, is set to continue until July 2030.
This initial phase will evaluate the safety, tolerability, and efficacy of SBE303 in patients with advanced and treatment-resistant solid tumors.
SBE303 is an ADC compound designed to Target the nectin-4 protein, which is expressed in various solid tumors, including bladder, lung, and breast cancers.